No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients
(2017) In Seizure 45. p.169-171- Abstract
Purpose High initial serum concentrations increase the risk of cutaneous adverse reactions. Genetic variants of the main metabolizing isoenzyme, uridine diphosphate glucuronosyltransferase (UGT) 1A4 influence the elimination of lamotrigine (LTG). Our aim was to investigate the potential association between the two best studied variants, *2 (P24T) and *3 (L48V), and the occurrence non-bullous skin reactions from LTG. Method The study included 29 patients of Caucasian ethnicity with a history of non-bullous skin reactions from LTG. 184 subjects tolerant to LTG for at least three months were used as controls. UGT1A4 genotyping was performed in all patients and controls by sequencing of the first part of exon 1. Six controls were excluded... (More)
Purpose High initial serum concentrations increase the risk of cutaneous adverse reactions. Genetic variants of the main metabolizing isoenzyme, uridine diphosphate glucuronosyltransferase (UGT) 1A4 influence the elimination of lamotrigine (LTG). Our aim was to investigate the potential association between the two best studied variants, *2 (P24T) and *3 (L48V), and the occurrence non-bullous skin reactions from LTG. Method The study included 29 patients of Caucasian ethnicity with a history of non-bullous skin reactions from LTG. 184 subjects tolerant to LTG for at least three months were used as controls. UGT1A4 genotyping was performed in all patients and controls by sequencing of the first part of exon 1. Six controls were excluded due to rare genetic variants. Results Two of 29 subjects (7%) with rash from LTG were heterozygous for UGT1A4 *2, compared to 23 of 178 (13%) tolerant controls (p = 0.54). Four of 29 subjects (14%) with rash from LTG were heterozygous for UGT1A4 *3 compared to 25 of 178 (14%) tolerant controls (p = 0.97). Conclusion It is unlikely that heterozygosity of the UGT1A4 genetic variants *2(P24T) or *3(L48V) influences the risk of non-bullous skin reactions in patients treated with LTG.
(Less)
- author
- Shirzadi, Maryam ; Reimers, Arne LU ; Helde, Grethe ; Sjursen, Wenche and Brodtkorb, Eylert
- publishing date
- 2017-02-01
- type
- Contribution to journal
- publication status
- published
- keywords
- Cutaneous adverse reaction, Lamotrigine, Polymorphisms, Serum concentration, UGT1A4
- in
- Seizure
- volume
- 45
- pages
- 3 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:28068583
- scopus:85008440361
- ISSN
- 1059-1311
- DOI
- 10.1016/j.seizure.2016.12.015
- language
- English
- LU publication?
- no
- additional info
- Publisher Copyright: © 2017 British Epilepsy Association
- id
- 0140df44-b0c7-4a01-9e11-34f3eef0f670
- date added to LUP
- 2024-08-31 14:43:21
- date last changed
- 2024-09-02 08:24:12
@article{0140df44-b0c7-4a01-9e11-34f3eef0f670,
abstract = {{<p>Purpose High initial serum concentrations increase the risk of cutaneous adverse reactions. Genetic variants of the main metabolizing isoenzyme, uridine diphosphate glucuronosyltransferase (UGT) 1A4 influence the elimination of lamotrigine (LTG). Our aim was to investigate the potential association between the two best studied variants, *2 (P24T) and *3 (L48V), and the occurrence non-bullous skin reactions from LTG. Method The study included 29 patients of Caucasian ethnicity with a history of non-bullous skin reactions from LTG. 184 subjects tolerant to LTG for at least three months were used as controls. UGT1A4 genotyping was performed in all patients and controls by sequencing of the first part of exon 1. Six controls were excluded due to rare genetic variants. Results Two of 29 subjects (7%) with rash from LTG were heterozygous for UGT1A4 *2, compared to 23 of 178 (13%) tolerant controls (p = 0.54). Four of 29 subjects (14%) with rash from LTG were heterozygous for UGT1A4 *3 compared to 25 of 178 (14%) tolerant controls (p = 0.97). Conclusion It is unlikely that heterozygosity of the UGT1A4 genetic variants *2(P24T) or *3(L48V) influences the risk of non-bullous skin reactions in patients treated with LTG.</p>}},
author = {{Shirzadi, Maryam and Reimers, Arne and Helde, Grethe and Sjursen, Wenche and Brodtkorb, Eylert}},
issn = {{1059-1311}},
keywords = {{Cutaneous adverse reaction; Lamotrigine; Polymorphisms; Serum concentration; UGT1A4}},
language = {{eng}},
month = {{02}},
pages = {{169--171}},
publisher = {{Elsevier}},
series = {{Seizure}},
title = {{No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients}},
url = {{http://dx.doi.org/10.1016/j.seizure.2016.12.015}},
doi = {{10.1016/j.seizure.2016.12.015}},
volume = {{45}},
year = {{2017}},
}